Adicet Bio, INC Form 4 insider transactions

Director Carl L. Gordon reports changes in beneficial ownership of Adicet Bio, Inc. stock options due to the rescission of a prior repricing.

Katie Peng, a director at Adicet Bio, had her stock options reverted to their original exercise price following the company's rescission of a prior repricing decision.

Jeffrey Chodakewitz, a director at Adicet Bio, adjusted his stock option holdings on August 21, 2024, following the board's decision to rescind a previous repricing of stock options for non-employee directors.

Director Steve Dubin's stock options in Adicet Bio were repriced back to their original exercise prices following a board decision to rescind a previous repricing.

Michael Kauffman, a director at Adicet Bio, had his stock options repricing rescinded, reverting them to their original exercise prices.

Aya Jakobovits, a director at Adicet Bio, reported adjustments to stock options due to the rescission of a prior repricing, according to a Form 4 filing.

Director Lloyd Klickstein acquired 70,200 stock options in Adicet Bio, Inc. on August 19, 2024, according to a Form 4 filing.

Chief Scientific Officer Aftab Blake reports the acquisition of stock options in Adicet Bio, Inc.

Francesco Galimi, SVP & Chief Medical Officer of Adicet Bio, Inc., reports the acquisition of stock options.

Adicet Bio's Chief Financial Officer, Brian Nicholas Harvey, acquired stock options for 374,829 shares of common stock on June 5, 2024.

Don Healey, Chief Technology Officer of Adicet Bio, reports the acquisition of stock options.

Chen Schor, President & CEO of Adicet Bio, Inc., acquired 1,770,427 stock options on June 5, 2024, at an exercise price of $2.53.

Director Carl L. Gordon reports acquisition of restricted stock units and stock options in Adicet Bio, Inc.

Director Jeffrey Chodakewitz reports acquisition of Adicet Bio shares and stock options, signaling changes in beneficial ownership.

Director Aya Jakobovits reports acquisition of stock options and restricted stock units in Adicet Bio, along with details of indirect beneficial ownership.

Director Steve Dubin acquired shares and options in Adicet Bio, Inc. on June 5, 2024, according to a Form 4 filing.

Director Michael Kauffman reports acquisition and disposal of Adicet Bio (ACET) common stock and stock options.

Director Katie Peng acquired 5,900 shares of common stock and options to purchase 26,400 shares of Adicet Bio, Inc. (ACET) on June 5, 2024.

Director Andrew Sinclair acquired shares and options in Adicet Bio, Inc. on June 5, 2024, according to a Form 4 filing.